Olema Pharmaceuticals D
D
OLMA
7.55500
USD
0.04
(0.47%)
Market Closed
Last updated: · Delayed 15 min
Volume
71,395
EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
-2
Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
-
P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
-3
Market CapWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
661,865,317
Title: Olema Oncology Inc
Sector: Healthcare
Industry: Biotechnology
Olema Oncology Inc is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The company's lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), is currently in two Phase 3 clinical trials. In addition, Olema is focused in developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor.